Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age With Leber Congenital Amaurosis Type 10 (LCA10) Due to the c.2991 +1655A>G (p.Cys998X) Mutation

Next Previous
Trial Profile

An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age With Leber Congenital Amaurosis Type 10 (LCA10) Due to the c.2991 +1655A>G (p.Cys998X) Mutation

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sepofarsen (Primary)
  • Indications Leber congenital amaurosis
  • Focus Adverse reactions
  • Acronyms BRIGHTEN
  • Sponsors ProQR Therapeutics

Most Recent Events

  • 13 Apr 2022 According to a ProQR Therapeutics media release, bsed on the recommendation of the Data Safety and Monitoring Committee (DSMC), the Company currently plans to continue this study, until further regulatory guidance, after which next steps will be determined.
  • 18 Nov 2021 According to a ProQR Therapeutics media release, enrollment of 5 patients in the open-label, dose-escalation portion of this study is complete, with the double masked randomization portion of the trial getting underway.
  • 18 Nov 2021 According to a ProQR Therapeutics media release, the company present data of this study at the Analyst Event via webcast.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top